Contact Us

Care is just a click away. 
Contact us to learn more:

This form does not yet contain any fields.
    « Statins and Aspirin May Help to Control Certain Cancers | Main | FDA Approves Trametinib for Metastatic Melanoma »
    Wednesday
    Jun122013

    Sorafenib (Nexavar) Nearly Doubles Progression-Free Survival in Metastatic Thyroid Cancer

    Sorafenib was originally approved for kidney cancer, then liver cancer.  GeneKey scientists were the first to identify its use in melanoma patients who failed BRAF inhibitors.  Now sorafenib has been found to be effective against radioactive iodine (RAI)-refractory differentiated thyroid cancer, and is poised to become the first new drug to be approved in this indication in over 40 years.  Results presented at the recent ASCO conference showed a near-doubling of progression-free survival compared to placebo, from 5.8 months to 10.8 months.

    While surprising to some, it is quite common for existing therapies to prove useful in new indications, and our researchers have often found potentially effective drugs for an individual patient’s cancer outside the standard treatment regimens for their type of cancer.  Sometimes it is a drug from another type of cancer, as in the case of Sorafenib.  Other times it is a drug that was not originally developed for cancer at all (as, for example, with statins).

    The biochemistry of individual cancers is so varied that we expect to find vast differences in optimal treatment approach within the same disease – and yet because a given cellular mechanism of cancer is often at play in a variety of cancers, there is great therapeutic cross-over potential from one disease to another.  For each of our patients, we are dedicated to finding a therapy that targets the exact issues that appear to be driving their cancer, rather than the issues expected in their disease type. 

    Full Coverage: http://www.medpagetoday.com/MeetingCoverage/ASCO/39545

    References (23)

    References allow you to track sources for this article, as well as articles that were written in response to this article.
    • Response
      Response: 時計 seiko
      時計 価格
    • Response
      ... לימודי אנגלית - בכיתות לימודי יפנית און ליין יותר לימודי האנגלית שלה מייד אחרי הלמידה לבגרות באנגלית או כאשר מדובר אנגלית. אם בעבר יכל אדם להעביר את רוב חייו במדינה אחת דיבר שפה אחת והסתדר מצוי... Sorafenib (Nexavar) Nearly Doubles Progression-Free Survival in ... ...
    • Response
      Sorafenib (Nexavar) Nearly Doubles Progression-Free Survival in Metastatic Thyroid Cancer - Latest Cancer News - Personalized Genomic Research and Treatment of YOUR Cancer - GeneKey
    • Response
      Response: alberta camp jobs
      Sorafenib (Nexavar) Nearly Doubles Progression-Free Survival in Metastatic Thyroid Cancer - Latest Cancer News - Personalized Genomic Research and Treatment of YOUR Cancer - GeneKey
    • Response
      Response: dvnf
      Sorafenib (Nexavar) Nearly Doubles Progression-Free Survival in Metastatic Thyroid Cancer - Latest Cancer News - Personalized Genomic Research and Treatment of YOUR Cancer - GeneKey
    • Response
      Sorafenib (Nexavar) Nearly Doubles Progression-Free Survival in Metastatic Thyroid Cancer - Latest Cancer News - Personalized Genomic Research and Treatment of YOUR Cancer - GeneKey
    • Response
      Response: autosummarize
      Whereas cancer begins, it always products no symptoms. Signs also indications sole seem as the mass continues to ulcerates. The findings that outcome rely on the type further location of the cancer.
    • Response
      Sorafenib (Nexavar) Nearly Doubles Progression-Free Survival in Metastatic Thyroid Cancer - Latest Cancer News - Personalized Genomic Research and Treatment of YOUR Cancer - GeneKey
    • Response
      Response: senuke
      Sorafenib (Nexavar) Nearly Doubles Progression-Free Survival in Metastatic Thyroid Cancer - Latest Cancer News - Personalized Genomic Research and Treatment of YOUR Cancer - GeneKey
    • Response
      Response: seo in utah
      It’s actually a terrific and beneficial part of facts. I’m fulfilled which you propagated this specific helpful facts with us
    • Response
      Response: emailsite.de
      Sorafenib (Nexavar) Nearly Doubles Progression-Free Survival in Metastatic Thyroid Cancer - Latest Cancer News - Personalized Genomic Research and Treatment of YOUR Cancer - GeneKey
    • Response
      Response: 2k a day bonus
      Sorafenib (Nexavar) Nearly Doubles Progression-Free Survival in Metastatic Thyroid Cancer - Latest Cancer News - Personalized Genomic Research and Treatment of YOUR Cancer - GeneKey
    • Response
      Response: http://vimeo.com/
      Sorafenib (Nexavar) Nearly Doubles Progression-Free Survival in Metastatic Thyroid Cancer - Latest Cancer News - Personalized Genomic Research and Treatment of YOUR Cancer - GeneKey
    • Response
      Response: seo norwalk
      Sorafenib (Nexavar) Nearly Doubles Progression-Free Survival in Metastatic Thyroid Cancer - Latest Cancer News - Personalized Genomic Research and Treatment of YOUR Cancer - GeneKey
    • Response
      Sorafenib (Nexavar) Nearly Doubles Progression-Free Survival in Metastatic Thyroid Cancer - Latest Cancer News - Personalized Genomic Research and Treatment of YOUR Cancer - GeneKey
    • Response
      Sorafenib (Nexavar) Nearly Doubles Progression-Free Survival in Metastatic Thyroid Cancer - Latest Cancer News - Personalized Genomic Research and Treatment of YOUR Cancer - GeneKey
    • Response
      Response: breaking news
      Sorafenib (Nexavar) Nearly Doubles Progression-Free Survival in Metastatic Thyroid Cancer - Latest Cancer News - Personalized Genomic Research and Treatment of YOUR Cancer - GeneKey
    • Response
      Response: bingo games
      Sorafenib (Nexavar) Nearly Doubles Progression-Free Survival in Metastatic Thyroid Cancer - Latest Cancer News - Personalized Genomic Research and Treatment of YOUR Cancer - GeneKey
    • Response
      Response: iphone videos
      Sorafenib (Nexavar) Nearly Doubles Progression-Free Survival in Metastatic Thyroid Cancer - Latest Cancer News - Personalized Genomic Research and Treatment of YOUR Cancer - GeneKey
    • Response
      Response: paper writing
      It is most useful writing service and these are all given good life to improve the essay writing services and more online writing services. Thank you so mucy to your blog writers and content writers.
    • Response
      Response: visit my web site
      Sorafenib (Nexavar) Nearly Doubles Progression-Free Survival in Metastatic Thyroid Cancer - Latest Cancer News - Personalized Genomic Research and Treatment of YOUR Cancer - GeneKey
    • Response
      Response: mad binocular
    • Response
      Response: Happy binocular

    Reader Comments

    There are no comments for this journal entry. To create a new comment, use the form below.

    PostPost a New Comment

    Enter your information below to add a new comment.

    My response is on my own website »
    Author Email (optional):
    Author URL (optional):
    Post:
     
    Some HTML allowed: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <code> <em> <i> <strike> <strong>